Most relapsing MS patients on Mavenclad did not have confirmed disability progression for at least four years, new Phase 4 ...
News-Medical.Net on MSN
Study identifies PTX-3 as potential marker for long COVID and tissue damage
A research team working at MedUni Vienna has demonstrated that a specific component of the immune system (PTX-3) remains at ...
Insights from ECTRIMS 2025, including anticipated presentations, key takeaways, and how emerging research on DMTs in RRMS may affect patient care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback